Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$13.76 ▼ -0.25
(-1.78%)
MKT CAP: $943.6M • VOL: 1.51M
52W L $10 52W H $36
QDEL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-28 | FY 2024
FILED 2024-12-29 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.73B | $2.78B | $3.00B |
| YoY Revenue Growth % | -1.9% | -7.2% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$919.2M | -$1.96B | $139.1M |
| Operating Margin % | -33.7% | -70.5% | 4.6% |
| Net Income (GAAP) | -$1.13B | -$2.05B | -$10.1M |
| EBITDA (Normalized) | -$768.6M | -$1.80B | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $105.2M | $83.0M | $280.2M |
| Capital Expenditures (CapEx) | $188.2M | $195.1M | — |
| Free Cash Flow (FCF) | -$83.0M | -$112.1M | $280.2M |
| FCF Margin % | -3.0% | -4.0% | 9.3% |
| Return on Invested Capital (ROIC %) | -41.5% | -45.0% | — |
| Cash & Short-Term Equivalents | $169.8M | $98.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.92B | $2.98B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR QDEL.